Literature DB >> 33765230

Bone Mineral Disease After Kidney Transplantation.

Josep-Vicent Torregrosa1,2, Ana Carina Ferreira3,4, David Cucchiari5, Aníbal Ferreira3,4.   

Abstract

Chronic kidney disease-mineral bone disorder (CKD-MBD) after kidney transplantation is a mix of pre-existing disorders and new alterations. The final consequences are reflected fundamentally as abnormal mineral metabolism (hypercalcemia, hypophosphatemia) and bone alterations [high or low bone turnover disease (as fibrous osteitis or adynamic bone disease), an eventual compromise of bone mineralization, decrease bone mineral density and bone fractures]. The major cause of post-transplantation hypercalcemia is the persistence of severe secondary hyperparathyroidism, and treatment options include calcimimetics or parathyroidectomy. On turn, hypophosphatemia is caused by both the persistence of high blood levels of PTH and/or high blood levels of FGF23, with its correction being very difficult to achieve. The most frequent bone morphology alteration is low bone turnover disease, while high-turnover osteopathy decreases in frequency after transplantation. Although the pathogenic mechanisms of these abnormalities have not been fully clarified, the available evidence suggests that there are a number of factors that play a very important role, such as immunosuppressive treatment, persistently high levels of PTH, vitamin D deficiency and hypophosphatemia. Fracture risk is four-fold higher in transplanted patients compared to general population. The most relevant risk factors for fracture in the kidney transplant population are diabetes mellitus, female sex, advanced age (especially > 65 years), dialysis vintage, high PTH levels and low phosphate levels, osteoporosis, pre-transplant stress fracture and high doses or prolonged steroids therapy. Treatment alternatives for CKD-MBD after transplantation include minimization of corticosteroids, use of calcium and vitamin D supplements, antiresorptives (bisphosphonates or Denosumab) and osteoformers (synthetic parathyroid hormone). As both mineral metabolism and bone disorders lead to increased morbidity and mortality, the presence of these changes after transplantation has to be prevented (if possible), minimized, diagnosed, and treated as soon as possible.

Entities:  

Keywords:  Bone disease; Fractures; Mineral metabolism; Renal transplantation

Year:  2021        PMID: 33765230     DOI: 10.1007/s00223-021-00837-0

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  79 in total

Review 1.  Calcium metabolism and skeletal problems after transplantation.

Authors:  Armando Torres; Victor Lorenzo; Eduardo Salido
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

2.  Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.

Authors:  Pieter Evenepoel; Ben Sprangers; Evelyne Lerut; Bert Bammens; Kathleen Claes; Dirk Kuypers; Björn Meijers; Yves Vanrenterghem
Journal:  Clin Transplant       Date:  2011-10-18       Impact factor: 2.863

Review 3.  Bone Disease after Kidney Transplantation.

Authors:  Antoine Bouquegneau; Syrazah Salam; Pierre Delanaye; Richard Eastell; Arif Khwaja
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

4.  Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations.

Authors:  A Torres; A P Rodríguez; M T Concepción; S García; M Rufino; B Martín; L Pérez; M Machado; E de Bonis; M Losada; D Hernández; V Lorenzo
Journal:  Nephrol Dial Transplant       Date:  1998       Impact factor: 5.992

Review 5.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

6.  Mineral metabolism disorders, vertebral fractures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study).

Authors:  Armando Torres; Vicens Torregrosa; Roberto Marcen; Josep María Campistol; Manuel Arias; Domingo Hernández; Constantino Fernández; Nuria Esforzado; Raphael Paschoalin; Nuria Pérez; Ana Isabel García; Montserrat Del Amo; Jaume Pomés; Ana González Rinne; Domingo Marrero; Estefanía Pérez; Fernando Henríquez; Juan Manuel Díaz; Irene Silva; Verónica López; Manuel Perello; David Ramos; Isabel Beneyto; José María Cruzado; Alberto Martínez Castelao; Juan Bravo; Minerva Rodríguez; Carmen Díaz; Josep Crespo; Fernando Anaya; María Luisa Rodríguez; Juan José Cubero; Pilar Pascual; Rafael Romero; Amado Andrés Belmonte; María Dolores Checa; Carlos Jiménez; Fernando Escuin; Marta Crespo; Marisa Mir; Gonzalo Gómez; Beatriz Bayes; María José González; Alex Gutiérrez; Marta Cuberes; Alberto Rodríguez Benoit; Teresa García; Francisco Llamas; Agustín Ortega; José Luis Conde; Carlos Gómez Alamillo
Journal:  Nefrologia       Date:  2016-04-28       Impact factor: 2.033

7.  Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.

Authors:  J-V Torregrosa; C Bergua; M J Martinez de Osaba; F Oppenheimer; J M Campistol
Journal:  Transplant Proc       Date:  2009 Jul-Aug       Impact factor: 1.066

8.  Calcium metabolism in the early posttransplantation period.

Authors:  Pieter Evenepoel; Barbara Van Den Bergh; Maarten Naesens; Hylke De Jonge; Bert Bammens; Kathleen Claes; Dirk Kuypers; Yves Vanrenterghem
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

Review 9.  Bone disease after renal transplantation.

Authors:  José R Weisinger; Raúl G Carlini; Eudocia Rojas; Ezequiel Bellorin-Font
Journal:  Clin J Am Soc Nephrol       Date:  2006-08-23       Impact factor: 8.237

10.  Association of time-updated plasma calcium and phosphate with graft and patient outcomes after kidney transplantation.

Authors:  Willemijn Y van der Plas; António W Gomes Neto; Stefan P Berger; Robert A Pol; Schelto Kruijff; Stephan J L Bakker; Martin H de Borst
Journal:  Am J Transplant       Date:  2021-01-12       Impact factor: 8.086

View more
  2 in total

1.  Bone in CKD, a Fascinating Evolving Topic.

Authors:  J Cannata-Andía; N Carrillo-López; A Ferreira
Journal:  Calcif Tissue Int       Date:  2021-04-06       Impact factor: 4.333

2.  Improvement of Mineral and Bone Disorders After Renal Transplantation.

Authors:  Ana Carina Ferreira; Marco Mendes; Cecília Silva; Patrícia Cotovio; Inês Aires; David Navarro; Fernando Caeiro; Rúben Ramos; Rute Salvador; Bruna Correia; Guadalupe Cabral; Fernando Nolasco; Aníbal Ferreira
Journal:  Transplantation       Date:  2022-03-08       Impact factor: 5.385

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.